Literature DB >> 2866798

Regulation of formation of factor XIIIa by its fibrin substrates.

S D Lewis, T J Janus, L Lorand, J A Shafer.   

Abstract

Thrombin-catalyzed release of activation peptide (AP) from plasma factor XIII was studied to characterize the regulation of this initial step in the activation of factor XIII zymogen (fibrin-stabilizing factor). High-performance liquid chromatography was used to monitor the kinetics of release of AP. Non-cross-linked polymeric fibrins I and II (polymerized des-A- and des-A,B-fibrinogens), physiological substrates of factor XIIIa, were shown to be potent promoters of thrombin-catalyzed release of activation peptide from factor XIII. These promoters are proposed to act by complexing factor XIII and reducing the apparent Km for thrombin-catalyzed release of AP. Since thrombin-catalyzed release of AP is inefficient in the absence of polymerized fibrin, this mode of regulation should minimize formation of factor XIIIa prior to the formation of its fibrin substrates. The promoting activity of polymeric fibrin was rapidly lost when catalytically competent factor XIIIa was allowed to form. This observation suggested the possibility that factor XIIIa catalyzed cross-linking of fibrin inactivates fibrin as a promoter for the thrombin-catalyzed release of AP from factor XIII. Consistent with this view, the thiol reagent S-methyl methanethiosulfonate inactivated factor XIIIa, blocked cross-linking of fibrin, and protected against loss of its promoter activity. This mode of feedback regulation of the activation process by catalytically active factor XIIIa may serve to ensure against continued generation of factor XIIIa after its fibrin substrates have been cross-linked.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2866798     DOI: 10.1021/bi00345a007

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  12 in total

1.  Transglutaminase-catalyzed crosslinking of the Aalpha and gamma constituent chains in fibrinogen.

Authors:  S N Murthy; J H Wilson; T J Lukas; Y Veklich; J W Weisel; L Lorand
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

2.  Studies on the basis for the properties of fibrin produced from fibrinogen-containing gamma' chains.

Authors:  Kevin R Siebenlist; Michael W Mosesson; Irene Hernandez; Leslie A Bush; Enrico Di Cera; John R Shainoff; James P Di Orio; Laurie Stojanovic
Journal:  Blood       Date:  2005-07-07       Impact factor: 22.113

3.  The Non-catalytic B Subunit of Coagulation Factor XIII Accelerates Fibrin Cross-linking.

Authors:  Masayoshi Souri; Tsukasa Osaki; Akitada Ichinose
Journal:  J Biol Chem       Date:  2015-03-25       Impact factor: 5.157

4.  Characterization of the gene for the a subunit of human factor XIII (plasma transglutaminase), a blood coagulation factor.

Authors:  A Ichinose; E W Davie
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

5.  Isolation of a fibrin-binding fragment from blood coagulation factor XIII capable of cross-linking fibrin(ogen).

Authors:  C S Greenberg; J J Enghild; A Mary; J V Dobson; K E Achyuthan
Journal:  Biochem J       Date:  1988-12-15       Impact factor: 3.857

Review 6.  Regulation of the activities of the mammalian transglutaminase family of enzymes.

Authors:  Cornelius Klöck; Chaitan Khosla
Journal:  Protein Sci       Date:  2012-11-09       Impact factor: 6.725

7.  Characterization of the reciprocal binding sites on human alpha-thrombin and factor XIII A-chain.

Authors:  K E Achyuthan
Journal:  Mol Cell Biochem       Date:  1998-01       Impact factor: 3.396

8.  The interaction between fibrinogen and zymogen FXIII-A2B2 is mediated by fibrinogen residues γ390-396 and the FXIII-B subunits.

Authors:  James R Byrnes; Clare Wilson; Anthony M Boutelle; Chase B Brandner; Matthew J Flick; Helen Philippou; Alisa S Wolberg
Journal:  Blood       Date:  2016-08-25       Impact factor: 22.113

9.  Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy.

Authors:  P J Hogg; C M Jackson
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

10.  Autoimmune antibody (IgG Kansas) against the fibrin stabilizing factor (factor XIII) system.

Authors:  L Lorand; P T Velasco; J R Rinne; M Amare; L K Miller; M L Zucker
Journal:  Proc Natl Acad Sci U S A       Date:  1988-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.